Prof Jeremy Teoh invites the urological community to participate in #SIU2024NewDelhi. Join us Oct 23–26 to enjoy relevant scientific programming alongside colleagues from around the world. Review programme bit.ly/3U1XaN6 Register today and save bit.ly/3xv2JLd

Implementing nadofaragene firadenovec treatment in #NMIBC. Mark Tyson, Aimee Boden, & Meghann Davis Mayo Clinic join Zach Klaassen Georgia Cancer Center to discuss implementation and logistics and the importance of a comprehensive and collaborative approach > bit.ly/3TJBlk3

#Uroonco24 congress excellent session on bladder cancer NMIBC UR intermediate risk management #many thanks to faculty Morgan Roupret & Carme Mir # Budapest

AI-based assessment tool for predicting BCG response in #BladderCancer pts. yair lotan UT Southwestern Urology joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss this innovative tool presented by Valar Labs aimed at refining the management of BCG-unresponsive bladder cancer > bit.ly/3VEE4O2

Merci The The New Yorker ! Paris 2024

🇫🇷

🎬 Sia Daneshmand, M.D. highlights the latest advancements in #bladder preservation strategies for patients with #NMIBC. 👀 Watch Now: buff.ly/3AnsQ8u

Timely! Just out from #IBCG23 as we wrap up #IBCG24: Bladder-sparing Therapy for BCG–unresponsive NMIBC: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection authors.elsevier.com/a/1jfA914kplyy… IBCG World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network

Addition of ARPIs to ADT increases the risk of cardiac disorders( ie., IHD, AF, & hypertension). Each ARPI exhibits a distinct cardiovascular event profile. Selecting patients carefully & vigilant monitoring for cardiovascular issues is imperative. nature.com/articles/s4139…

🗣️ Join me at the #BladderCancerForum24 on October 1-2 (face-to-face and virtual)! I'm speaking alongside experts & advocates in bladder cancer. Let's learn, share, and & shape the future of bladder cancer care together! Save your seat today👉 ow.ly/PtaR50Ta5FY

History in the making: at #ERUS24 Prof Alberto Breda performs a partial nephrectomy from Bordeaux, France on a patient nearly 10,000km away in Beijing, China.

HER3 EGFR Topo-1 ADC shows unconfirmed responses of 40%. The numbers are small but the MOA is novel and the data looks good. Adverse events are driven by Topo-1 toxicity. This agent is exciting should be further investigated alone and in combination in randomised trials #ESM024

#ESMO24-The current treatment landscape in mUC

#ESMO24 Presidential Session : Practice-changing trials - EORTC GUCG Peace 3 trial mCRPC Combination enzalutamide +6 cycles of Ra223 shows significant improvement in PFS & OS

Congratulations Andrea Apolo, M.D. and the @alliance team for the ph 3 Ambassador trial data showing improved disease free survival with pembrolizumab in MIBC after surgery #bladdercancer 👇Terrific presentation and Simultaneously published NEJM paper👇 ESMO - Eur. Oncology #ESMO24 OncoAlert

#ESMO24 • NIAGARA is the first Phase 3 perioperative immunotherapy study in MIBC and has demonstrated a statistically significant and clinically meaningful improvement in EFS and OS

#ESMO24 - Tombola trial - Serial measurements of cDNA following NAC and RC is a highly specific method to identify patients that might benefit from early immunotherapy at a time of minimal metastatic disease

The #ARANOTE trial shows that the addition of #darolutamide to ADT in pts with mHSPC significantly improved rPFS and was associated with a positive trend for OS! OncoAlert #esmo2024 ESMO - Eur. Oncology

#ESMO24 what an extraordinary congress, full of groundbreaking news and therapeutic advancements. Glad to have reconnected with colleagues and friends. See you all in Berlin for ESMO 2025!

The 6th #B2BGUCancersTriad is officially a month away! We look forward to welcoming experts and delegates from around the world to participate in this engaging session. The #B2BGUCancersTriad will feature leading scientific research & advances in the management of bladder,